Regenesis utilizes mESh nanotechnology to provide in situ electrical stimulation for the regeneration of cartilage lesions and osteochondral defects. This approach addresses pain and functional loss in patients, enabling quicker recovery and a return to normal activities.
Funding
Funding not disclosed
Founders
Product
Problem
Osteochondral defects, resulting from injuries, affect both cartilage and underlying bone, leading to pain, loss of function, and potential long-term complications like post-traumatic osteoarthritis. Current treatments often fail to fully regenerate cartilage, leaving patients with persistent symptoms and limited mobility.
Solution
Regenesis utilizes mESh nanotechnology to deliver in situ electrical stimulation directly to cartilage lesions and osteochondral defects, promoting tissue regeneration. This approach aims to accelerate healing, reduce pain, and improve joint function, enabling patients to return to normal activities more quickly. The mESh technology provides a localized and controlled electrical field that stimulates cellular activity and enhances the body's natural regenerative processes. By addressing the underlying cause of cartilage damage, Regenesis offers a potential solution for long-term joint health and improved quality of life.
Target Audience
The primary target audience includes patients with osteochondral defects resulting from sports injuries, workplace accidents, or other trauma, as well as orthopedic surgeons and sports medicine physicians seeking advanced cartilage regeneration solutions.
Features
- mESh nanotechnology for targeted delivery of electrical stimulation
- In situ application directly to cartilage lesions and osteochondral defects
- Promotion of tissue regeneration at the cellular level
- Reduction of pain and improvement of joint function